Sms Pharmaceuticals Ltd. | Small-cap | Healthcare
₹268.84
4.21%
| Sms Pharmaceuticals Stock Comparison:
Sms Pharmaceuticals vs GlaxoSmithKlineSms Pharmaceuticals vs PfizerSms Pharmaceuticals vs SenoresSms Pharmaceuticals vs TTK HealthcareSms Pharmaceuticals vs KopranSms Pharmaceuticals vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 2.0B
Gross Profit 653.5M 33.33%
Operating Income 296.2M 15.11%
Net Income 204.9M 10.45%
EPS (Diluted) ₹2.31

Balance Sheet Metrics

Total Assets 11.5B
Total Liabilities 5.1B
Shareholders Equity 6.4B
Debt to Equity 0.80

Cash Flow Metrics

Revenue & Profitability Trend

Sms Pharmaceuticals Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i7.8B7.1B5.2B5.2B5.6B
Cost of Goods Sold i5.2B5.0B3.9B3.3B3.8B
Gross Profit i2.6B2.1B1.3B1.8B1.8B
Gross Margin % i32.8%29.5%24.8%35.2%32.4%
Operating Expenses
Research & Development i128.3M111.1M89.2M--
Selling, General & Administrative i211.7M142.1M93.2M83.7M92.0M
Other Operating Expenses i58.3M52.5M46.9M45.5M35.8M
Total Operating Expenses i398.3M305.7M229.3M129.2M127.8M
Operating Income i1.0B852.5M224.8M824.7M988.6M
Operating Margin % i13.4%12.1%4.3%16.0%17.6%
Non-Operating Items
Interest Income i6.9M7.6M7.7M5.6M3.1M
Interest Expense i174.3M226.2M209.9M181.6M102.5M
Other Non-Operating Income-----
Pre-tax Income i923.4M661.1M53.5M685.0M911.2M
Income Tax i249.4M169.1M14.6M6.2M301.6M
Effective Tax Rate % i27.0%25.6%27.4%0.9%33.1%
Net Income i691.4M498.3M-70.6M622.2M625.3M
Net Margin % i8.9%7.1%-1.4%12.1%11.1%
Key Metrics
EBITDA i1.4B1.2B585.2M1.2B1.2B
EPS (Basic) i₹8.16₹5.89₹-0.83₹7.35₹7.39
EPS (Diluted) i₹8.16₹5.89₹-0.83₹7.35₹7.39
Basic Shares Outstanding i8865203084652000846520008465200084652000
Diluted Shares Outstanding i8865203084652000846520008465200084652000

Income Statement Trend

Sms Pharmaceuticals Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i414.0M360.4M73.1M465.8M404.2M
Short-term Investments i914.0K34.4M66.9M3.5M4.5M
Accounts Receivable i2.0B2.4B1.5B485.2M1.1B
Inventory i2.8B2.3B2.2B2.5B1.4B
Other Current Assets146.4M227.5M189.7M260.5M1.0K
Total Current Assets i5.5B5.3B4.1B3.8B3.1B
Non-Current Assets
Property, Plant & Equipment i298.4M282.9M119.3M131.9M139.9M
Goodwill i21.3M26.6M14.7M13.7M16.0M
Intangible Assets i21.3M26.6M14.7M13.7M16.0M
Long-term Investments-----
Other Non-Current Assets89.9M138.7M56.1M43.0M56.3M
Total Non-Current Assets i6.0B5.0B4.7B4.8B5.0B
Total Assets i11.5B10.3B8.8B8.6B8.1B
Liabilities
Current Liabilities
Accounts Payable i1.1B1.5B1.1B728.6M654.4M
Short-term Debt i1.7B1.6B1.3B1.1B1.0B
Current Portion of Long-term Debt-----
Other Current Liabilities45.9M48.3M15.2M26.8M33.5M
Total Current Liabilities i3.2B3.3B2.5B2.0B2.0B
Non-Current Liabilities
Long-term Debt i1.4B1.2B1.2B1.5B1.5B
Deferred Tax Liabilities i481.0M428.0M410.2M395.5M538.5M
Other Non-Current Liabilities-----
Total Non-Current Liabilities i1.9B1.7B1.6B1.9B2.1B
Total Liabilities i5.1B5.0B4.2B3.9B4.0B
Equity
Common Stock i88.7M84.7M84.7M84.7M84.7M
Retained Earnings i3.8B3.2B2.9B3.0B2.5B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i6.4B5.4B4.6B4.7B4.1B
Key Metrics
Total Debt i3.1B2.8B2.5B2.6B2.5B
Working Capital i2.3B2.0B1.6B1.8B1.1B

Balance Sheet Composition

Sms Pharmaceuticals Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i923.4M661.1M53.5M685.0M911.2M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-72.1M-1.0B-770.2M-643.3M-334.4M
Operating Cash Flow i1.0B-141.5M-507.2M217.6M630.3M
Investing Activities
Capital Expenditures i-1.2B-520.7M-296.6M-272.3M-1.5B
Acquisitions i-----
Investment Purchases i-149.0K-65.0K-1.7M0-
Investment Sales i-----
Investing Cash Flow i-1.2B-522.3M-299.1M-274.3M-1.5B
Financing Activities
Share Repurchases i-----
Dividends Paid i-33.9M-25.4M-25.4M-25.4M-
Debt Issuance i637.2M450.9M94.1M451.9M1.1B
Debt Repayment i-441.0M-377.6M-430.6M-366.7M-192.9M
Financing Cash Flow i651.3M534.7M-103.1M30.3M961.4M
Free Cash Flow i-416.7M-20.4M-74.7M178.1M-613.0M
Net Change in Cash i440.4M-129.1M-909.4M-26.4M73.9M

Cash Flow Trend

Sms Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 28.80
Price to Book 3.40
Price to Sales 2.84
PEG Ratio 1.56

Profitability Ratios

Profit Margin 8.98%
Operating Margin 15.11%
Return on Equity 10.81%
Return on Assets 6.00%

Financial Health

Current Ratio 1.71
Debt to Equity 48.58
Beta 0.54

Per Share Data

EPS (TTM) ₹8.53
Book Value per Share ₹72.15
Revenue per Share ₹94.94

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
smspharma23.1B28.803.4010.81%8.98%48.58
GlaxoSmithKline 458.6B47.3923.0947.54%25.41%0.51
Pfizer 231.6B28.685.4618.20%34.83%2.57
Senores 32.9B48.744.267.21%14.82%38.75
TTK Healthcare 16.3B25.791.537.67%7.69%2.27
Kopran 8.8B24.121.627.44%5.58%28.51

Financial data is updated regularly. All figures are in the company's reporting currency.